Invention Grant
- Patent Title: Anti-CEACAM6 antibodies and uses thereof
-
Application No.: US15561013Application Date: 2016-03-21
-
Publication No.: US10584167B2Publication Date: 2020-03-10
- Inventor: Jörg Willuda , Mark Trautwein , Uwe Gritzan , Christoph Freiberg , Frank Dittmer , Dorian Schönfeld , Julian Marius Glück , Jessica Pinkert , Eva-Maria Gutierrez , Sven Golfier , Simon Holton , Philip Beckhove , Yingzi Ge
- Applicant: Bayer Pharma Aktiengesellschaft
- Applicant Address: DE Berlin
- Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee: Bayer Pharma Aktiengesellschaft
- Current Assignee Address: DE Berlin
- Agency: Morrison & Foerster LLP
- Priority: EP15160292 20150323
- International Application: PCT/EP2016/056104 WO 20160321
- International Announcement: WO2016/150899 WO 20160929
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61P35/00

Abstract:
The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for human and Macaca fascicularis CEACAM6 (Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, Non-specific crossreacting antigen, NCA, NCA-50/90), and which do not significantly cross-react with the closely related human CEACAM1, human CEACAM3, and human CEACAM5. The invention further provides methods to generate this kind of antibodies. The antibodies, accordingly, can be used to treat cancer and other disorders and conditions associated with expression of the CEACAM6. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
Public/Granted literature
- US20180162940A1 ANTI-CEACAM6 ANTIBODIES AND USES THEREOF Public/Granted day:2018-06-14
Information query